The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Open accessAbstract
The systematic translation of cancer genomic data into knowledge of tumour biology and therapeutic possibilities remains challenging. Such efforts should be greatly aided by robust preclinical model systems that reflect the genomic diversity of human cancers and for which detailed genetic and pharmacological annotation is available. Here we describe the Cancer Cell Line Encyclopedia (CCLE): a compilation of gene expression, chromosomal copy number and massively parallel sequencing data from 947 human cancer cell lines. When coupled with pharmacological profiles for 24 anticancer drugs across 479 of the cell lines, this collection allowed identification of genetic, lineage, and gene-expression-based predictors of drug sensitivity. In addition to known predictors, we found that plasma cell lineage correlated with sensitivity to IGF1 receptor inhibitors; AHR expression was associated with MEK inhibitor efficacy in NRAS-mutant lines; and SLFN11 expression predicted sensitivity to topoisomerase inhibitors. Together, our results indicate that large, annotated cell-line collections may help to enable preclinical stratification schemata for anticancer agents. The generation of genetic predictions of drug response in the preclinical setting and their incorporation into cancer clinical trial design could speed the emergence of 'personalized' therapeutic regimens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The CCLE dataset has previously been used to identify biomarkers for drug resistance and susceptibility (Barretina et al., 2012).”
From Efficient Parameter Estimation Enables the Prediction of Drug Response Using a Mechanistic Pan-Cancer Pathway Model (2018) · cites this paper as Barretina et al., 2012
In the citing paper
“JDQ443 antiproliferative activity was assessed by a high-throughput cell viability assay in a large panel of KRASG12C-mutated (N = 17) and non–G12C-mutated (N = 225) cell lines from the Cancer Cell Line Encyclopedia (29). JDQ443 demonstrated potent antiproliferative activity selectively toward the KRASG12C-mutated lines (Fig. 2A and B).”
In the citing paper
“However, large-scale drug sensitivity studies using the MEK and ERK inhibitors did not reveal the same degree of selectivity in KRAS mutant cells (69, 70) (Figure 4).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [69]
In the citing paper
“Large-scale efforts aimed at linking tumor genomic alterations with sensitivity to cytotoxic and targeted therapies have uncovered a wealth of pharmacogenomic interactions in NSCLC and other cancer types149–152.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [151]
In the citing paper
“interrogation of the expression data from the cancer cell line encyclopedia20 (CCLE) database revealed that classical SCLC cell lines have significantly reduced levels of EGFR mRNA compared with adenocarcinoma cell lines”
From RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer (2015) · cites this paper as [20]
In the citing paper
“Other expression datasets integrated into the latest version are the Cancer Cell Line Encyclopedia (16) and cell perturbation expression data from the Library of Integrated Network-Based Cellular Signatures (17).”
From TCRD and pharos 2021: mining the human proteome for disease biology (2021) · cites this paper as [16]
In the citing paper
“The Passport model name is accompanied by synonyms and most importantly unique identifiers utilized by established resources such as Research Resource Identifiers (RRID) (19), the Catalogue of Somatic Mutations in Cancer (COSMIC) (20) and CCLE (6) to aid data integration and alignment.”
From Cell Model Passports-a hub for clinical, genetic and functional datasets of preclinical cancer models (2019) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regularization and Variable Selection Via the Elastic Net
Zou, H., & Hastie, T. (2005) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.1467-9868.2005.00503.x · Cited by 20,957
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Self-citationA collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppé, J., Tong, F. K., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.008 · Cited by 3,224
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456
Systematic variation in gene expression patterns in human cancer cell lines
Ross, D. T., Scherf, U., Eisen, M. B., Perou, C. M., Rees, C., Spellman, P., Iyer, V., Jeffrey, S. S., Van de Rijn, M., Waltham, M., et al. (2000) · Nature Genetics · doi:10.1038/73432 · Cited by 2,088
Garraway, L. A., Widlund, H. R., Rubin, M. A., Getz, G., Berger, A. J., Ramaswamy, S., Beroukhim, R., Milner, D. A., Granter, S. R., Du, J., et al. (2005) · Nature · doi:10.1038/nature03664 · Cited by 1,548
Self-citationDiscovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N. K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711741105 · Cited by 1,346
Self-citationBRAF mutation predicts sensitivity to MEK inhibition
Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G. A., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2005) · Nature · doi:10.1038/nature04304 · Cited by 1,326
Self-citationAn Information-Intensive Approach to the Molecular Pharmacology of Cancer
Weinstein, J. N., Myers, T. G., O'Connor, P. M., Friend, S. H., Fornace, A. J., Kohn, K. W., Fojo, T., Bates, S. E., Rubinstein, L., Anderson, N. L., et al. (1997) · Science · doi:10.1126/science.275.5298.343 · Cited by 1,183
High-throughput oncogene mutation profiling in human cancer
Thomas, R. K., Baker, A. C., Debiasi, R. M., Winckler, W., LaFramboise, T., Lin, W. M., Wang, M., Feng, W., Zander, T., MacConaill, L. E., et al. (2007) · Nature Genetics · doi:10.1038/ng1975 · Cited by 978
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 801–900 of 1,107
Liu, X., Song, C., Huang, F. F., Fu, H., Xiao, W., & Zhang, W. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab457 · Cited by 127
De novo pyrimidine biosynthetic complexes support cancer cell proliferation and ferroptosis defence
Yang, C., Zhao, Y., Wang, L., Guo, Z., Ma, L., Yang, R., Wu, Y., Li, X., Niu, J., Chu, Q., et al. (2023) · Nature Cell Biology · doi:10.1038/s41556-023-01146-4 · Cited by 131
Self-citationExtending the small-molecule similarity principle to all levels of biology with the Chemical Checker
Duran-Frigola, M., Pauls, E., Guitart-Pla, O., Bertoni, M., Alcalde, V., Amat, D., Juan-Blanco, T., & Aloy, P. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0502-7 · Cited by 126
TrAp: a tree approach for fingerprinting subclonal tumor composition
Strino, F., Parisi, F., Micsinai, M., & Kluger, Y. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt641 · Cited by 126
Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer
Abazeed, M. E., Adams, D., Hurov, K. E., Tamayo, P., Creighton, C. J., Sonkin, D., Giacomelli, A. O., Du, C., Fries, D. F., Wong, K., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1616 · Cited by 128
Self-citationGao, Q., Wang, Z.-C., Duan, M., Lin, Y.-H., Zhou, X., Worthley, D. L., Wang, X.-Y., Niu, G., Xia, Y., Deng, M., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.09.008 · Cited by 128
Variable importance‐weighted Random Forests
Liu, Y., & Zhao, H. (2017) · Quantitative Biology · doi:10.1007/s40484-017-0121-6 · Cited by 126
Albacker, L. A., Wu, J., Smith, P. G., Warmuth, M., Stephens, P. J., Zhu, P., Yu, L., & Chmielecki, J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176181 · Cited by 128
Self-citationZheng, X., Vis, D. J., Bruna, A., Šuštić, T., van Wageningen, S., Batra, A. S., Rueda, O. M., Bosdriesz, E., Caldas, C., Wessels, L. F. A., et al. (2018) · Cell Research · doi:10.1038/s41422-018-0044-4 · Cited by 123
Oxidative Stress in Cells with Extra Centrosomes Drives Non-Cell-Autonomous Invasion
Arnandis, T., Monteiro, P., Adams, S. D., Bridgeman, V. L., Rajeeve, V., Gadaleta, E., Marzec, J., Chelala, C., Malanchi, I., Cutillas, P. R., et al. (2018) · Developmental Cell · doi:10.1016/j.devcel.2018.10.026 · Cited by 121
Autotaxin in the crosshairs: Taking aim at cancer and other inflammatory conditions
Benesch, M. G. K., Ko, Y. M., McMullen, T. P. W., & Brindley, D. N. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.02.009 · Cited by 129
The mutational landscape of chromatin regulatory factors across 4,623 tumor samples
González-Pérez, A., Jené-Sanz, A., & López-Bigas, N. (2013) · Genome biology · doi:10.1186/gb-2013-14-9-r106 · Cited by 131
E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer
Bajrami, I., Marlow, R., van de Ven, M., Brough, R., Pemberton, H. N., Frankum, J. R., Song, F., Rafiq, R., Konde, A., Krastev, D. B., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0603 · Cited by 125
A novel heterogeneous network-based method for drug response prediction in cancer cell lines
Zhang, F., Wang, M., Xi, J., Yang, J., & Li, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-21622-4 · Cited by 125
Miner, K. T., Labitzke, K., Liu, B., Wang, P., Henckels, K., Gaida, K., Elliott, R., Chen, J. J., Liu, L., Leith, A., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00051 · Cited by 122
Self-citationLi, R., Ng, T. S. C., Wang, S. J., Prytyskach, M., Rodell, C. B., Mikula, H., Köhler, R. H., Garlin, M. A., Lauffenburger, D. A., Parangi, S., et al. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00897-1 · Cited by 130
Epithelial-to-Mesenchymal Transition Rewires the Molecular Path to PI3K-Dependent Proliferation
Salt, M. B., Bandyopadhyay, S., & McCormick, F. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0520 · Cited by 124
The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies
Earl, J., Rico, D., Pau, E. C. D. S., Rodríguez‐Santiago, B., Méndez‐Pertuz, M., Auer, H., Goméz-López, G., Grossman, H. B., Pisano, D. G., Schulz, W. A., et al. (2015) · BMC Genomics · doi:10.1186/s12864-015-1450-3 · Cited by 124
A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer
Dietlein, F., Kalb, B., Jokić, M., Noll, E. M., Strong, A., Tharun, L., Ozretić, L., Künstlinger, H., Kambartel, K.-O., Randerath, W. J., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.053 · Cited by 126
Kubota, E., Williamson, C. T., Ye, R., Elegbede, A. A., Peterson, L., Lees‐Miller, S. P., & Bebb, D. G. (2014) · Cell Cycle · doi:10.4161/cc.29212 · Cited by 125
Identification of an oncogenic RAB protein
Wheeler, D. B., Zoncu, R., Root, D. E., Sabatini, D. M., & Sawyers, C. L. (2015) · Science · doi:10.1126/science.aaa4903 · Cited by 125
Vougas, K. N., Sakellaropoulos, T., Kotsinas, A., Foukas, G.-R. P., Ntargaras, A., Koinis, F., Polyzos, A., Myrianthopoulos, V., Zhou, H., Narang, S., et al. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107395 · Cited by 129
Takeda, H., Wei, Z., Koso, H., Rust, A. G., Yew, C. C. K., Mann, M. B., Ward, J. M., Adams, D. J., Copeland, N. G., & Jenkins, N. A. (2015) · Nature Genetics · doi:10.1038/ng.3175 · Cited by 124
Garner, A. P., Bialucha, C. U., Sprague, E. R., Garrett, J. T., Sheng, Q., Li, S., Sineshchekova, O., Saxena, P., Sutton, C. R., Chen, D., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1198 · Cited by 125
Self-citationZhou, C., Liu, C., Liu, W., Chen, W., Yin, Y., Li, C.-W., Hsu, J. L., Sun, J., Zhou, Q., Li, H., et al. (2020) · Theranostics · doi:10.7150/thno.42869 · Cited by 121
CanDrA: Cancer-Specific Driver Missense Mutation Annotation with Optimized Features
Mao, Y., Chen, H., Liang, H., Meric‐Bernstam, F., Mills, G. B., & Chen, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077945 · Cited by 123
Nakanishi, Y., Akiyama, N., Tsukaguchi, T., Fujii, T., Sakata, K., Sase, H., Isobe, T., Morikami, K., Shindoh, H., Mio, T., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0248 · Cited by 121
Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape
Olaussen, K. A., & Postel-Vinay, S. C. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw321 · Cited by 124
Montoya, A., Amaya, C. N., Belmont, A., Diab, N., Trevino, R., Villanueva, G., Rains, S., Sanchez, L. A., Badri, N., Otoukesh, S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.14119 · Cited by 122
Soderquist, R. S., Crawford, L. A., Liu, E., Lu, M., Agarwal, A., Anderson, G. R., Lin, K., Winter, P. S., Çakır, M., & Wood, K. C. (2018) · Nature Communications · doi:10.1038/s41467-018-05815-z · Cited by 122
Jia, Y., Juarez, J., Li, J., Manuia, M., Niederst, M. J., Tompkins, C., Timple, N., Vaillancourt, M.-T., Pferdekamper, A. C., Lockerman, E. L., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2581 · Cited by 121
Self-citationTsang, Y. T. M., Deavers, M. T., Sun, C. C., Kwan, S., Kuo, E., Malpica, A. L., Mok, S. C., Gershenson, D. M., & Wong, K. (2013) · The Journal of Pathology · doi:10.1002/path.4252 · Cited by 119
Sparse integrative clustering of multiple omics data sets
Shen, R., Wang, S., & Mo, Q. (2013) · The Annals of Applied Statistics · doi:10.1214/12-aoas578 · Cited by 121
Grassian, A. R., Lin, F., Barrett, R., Liu, Y., Jiang, W., Korpal, M., Astley, H. M., Gitterman, D. P., Henley, T., Howes, R., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.417832 · Cited by 122
Smith, M. A., Reynolds, C. P., Kang, M. H., Kolb, E. A., Gorlick, R. G., Carol, H., Lock, R. B., Keir, S. T., Maris, J. M., Billups, C. A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2572 · Cited by 122
Buettner, R., Wolf, J., & Thomas, R. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.9867 · Cited by 123
Cea, M., Cagnetta, A., Adamia, S., Acharya, C., Tai, Y., Fulciniti, M., Ohguchi, H., Munshi, A., Acharya, P. C., Bhasin, M., et al. (2015) · Blood · doi:10.1182/blood-2015-06-649970 · Cited by 121
Vallejo, M. J., Salazar, L., & Grijalva, M. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/4586068 · Cited by 125
Systematic identification of non-coding pharmacogenomic landscape in cancer
Wang, Y., Wang, Z., Xu, J., Jiang, L., Song, L., Zhang, M., & Yang, D. (2018) · Nature Communications · doi:10.1038/s41467-018-05495-9 · Cited by 121
Unsupervised correction of gene-independent cell responses to CRISPR-Cas9 targeting
Iorio, F., Behan, F. M., Gonçalves, E., Bhosle, S. G., Chen, E. D., Shepherd, R., Beaver, C., Ansari, R. A., Pooley, R., Wilkinson, P., et al. (2018) · BMC Genomics · doi:10.1186/s12864-018-4989-y · Cited by 120
A High-Resolution Map of Human Enhancer RNA Loci Characterizes Super-enhancer Activities in Cancer
Chen, H., & Liang, H. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.020 · Cited by 125
Etemadmoghadam, D., Au‐Yeung, G., Wall, M., Mitchell, T. J., Kansara, M., Loehrer, E. A., Batzios, C., George, J., Ftouni, S., Weir, B. A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1337 · Cited by 120
Self-citationRSPO–LGR4 functions via IQGAP1 to potentiate Wnt signaling
Carmon, K. S., Gong, X. W., Yi, J., Thomas, A., & Liu, Q. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323106111 · Cited by 121
Walsh, L. A., Alvarez, M. J., Sabio, E. Y., Reyngold, M., Makarov, V., Mukherjee, S., Lee, K.-W., Desrichard, A., Turcan, Ş., Dalin, M. G., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.07.052 · Cited by 118
Short-chain fatty acid receptors inhibit invasive phenotypes in breast cancer cells
Thirunavukkarasan, M., Wang, C., Rao, A., Hind, T., Teo, Y. L., Siddiquee, A. A.-M., Goghari, M. A. I., Kumar, A. P., & Herr, D. R. (2017) · PLoS ONE · doi:10.1371/journal.pone.0186334 · Cited by 124
An alternative splicing switch in FLNB promotes the mesenchymal cell state in human breast cancer
Li, J., Choi, P. S., Chaffer, C. L., Labella, K., Hwang, J. H., Giacomelli, A. O., Kim, J. W., Ilić, N., Doench, J. G., Ly, S. H., et al. (2018) · eLife · doi:10.7554/elife.37184 · Cited by 116
GraphSynergy: a network-inspired deep learning model for anticancer drug combination prediction
Yang, J., Xu, Z., Wu, W. K. K., Chu, Q., & Zhang, Q. (2021) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocab162 · Cited by 121
MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells
Wang, Y., Lee, Y., Baitsch, L., Huang, A., Xiang, Y., Tong, H., Lako, A., Von, T., Choi, C. H., Lim, E., et al. (2014) · eLife · doi:10.7554/elife.01763 · Cited by 118
Self-citationStiffness of pancreatic cancer cells is associated with increased invasive potential
Nguyen, A. V., Nyberg, K. D., Scott, M., Welsh, A. M., Nguyen, A. H., Wu, N., Hohlbauch, S. V., Geisse, N. A., Gibb, E. A., Robertson, A. G., et al. (2016) · Integrative Biology · doi:10.1039/c6ib00135a · Cited by 124
Interferon-γ Signaling in Melanocytes and Melanoma Cells Regulates Expression of CTLA-4
Mo, X., Zhang, H., Preston, S., Martin, K. A., Zhou, B., Vadalia, N., Gamero, A. M., Soboloff, J., Tempera, I., & Zaidi, M. R. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1615 · Cited by 125
Casara, P., Davidson, J. E. P., Clapéron, A., Toumelin-Braizat, G. L., Vogler, M., Bruno, A., Chanrion, M., Lysiak-Auvity, G., Diguarher, T. L., Starck, J.-B., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24744 · Cited by 119
Lima, Z. S., Ghadamzadeh, M., Arashloo, F. T., Amjad, G., Ebadi, M. R., & Younesi, L. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0725-6 · Cited by 123
The multifunctional APE1 DNA repair–redox signaling protein as a drug target in human disease
Caston, R. A., Gampala, S., Armstrong, L., Messmann, R. A., Fishel, M. L., & Kelley, M. R. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.10.015 · Cited by 116
Rambow, F., Job, B., Petit, V., Gesbert, F., Delmas, V., Seberg, H., Meurice, G., Otterloo, E. V., Dessen, P., Robert, C., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.09.037 · Cited by 123
Iskar, M., Zeller, G., Blattmann, P., Campillos, M., Kuhn, M., Kaminska, K. H., Runz, H., Gavin, A., Pepperkok, R., van Noort, V., et al. (2013) · Molecular Systems Biology · doi:10.1038/msb.2013.20 · Cited by 118
Genomic Medicine Frontier in Human Solid Tumors: Prospects and Challenges
Dienstmann, R., Rodon, J. A., Barretina, J., & Tabernero, J. M. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2268 · Cited by 120
Self-citationBrachmann, S. M., Kleylein-Sohn, J., Gaulis, S., Kauffmann, A., Blommers, M. J. J., Kazic-Legueux, M., Laborde, L., Hattenberger, M., Stauffer, F., Vaxelaire, J., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-1021 · Cited by 121
Self-citationAmmad-ud-din, M., Khan, S. A., Malani, D., Murumägi, A., Kallioniemi, O., Aittokallio, T. A., & Samuel Kaski, A. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw433 · Cited by 116
SPA70 is a potent antagonist of human pregnane X receptor
Lin, W., Wang, Y., Chai, S. C., Lv, L., Zheng, J., Wu, J., Zhang, Q., Wang, Y., Griffin, P. R., & Chen, T. (2017) · Nature Communications · doi:10.1038/s41467-017-00780-5 · Cited by 122
Karageorgis, G., Reckzeh, E. S., Ceballos, J., Schwalfenberg, M., Sievers, S., Ostermann, C., Pahl, A., Ziegler, S., & Waldmann, H. (2018) · Nature Chemistry · doi:10.1038/s41557-018-0132-6 · Cited by 118
Yap regulates glucose utilization and sustains nucleotide synthesis to enable organ growth
Cox, A. G., Tsomides, A., Yimlamai, D., Hwang, K. L., Miesfeld, J. B., Galli, G. G., Fowl, B. H., Fort, M. W., Kimberly, Y., Sullivan, M. R., et al. (2018) · The EMBO Journal · doi:10.15252/embj.2018100294 · Cited by 116
Cysteine Depletion, a Key Action to Challenge Cancer Cells to Ferroptotic Cell Death
Daher, B., Vučetić, M., & Pouysségur, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00723 · Cited by 124
Malik, V., Kalakoti, Y., & Sundar, D. (2021) · BMC Genomics · doi:10.1186/s12864-021-07524-2 · Cited by 117
ATARiS: Computational quantification of gene suppression phenotypes from multisample RNAi screensPreprint
Shao, D. D., Tsherniak, A., Gopal, S., Weir, B. A., Tamayo, P., Stransky, N., Schumacher, S. E., Zack, T. I., Beroukhim, R., Garraway, L. A., et al. (2012) · Genome Research · doi:10.1101/gr.143586.112 · Cited by 116
Self-citationYAP and TAZ modulate cell phenotype in a subset of small cell lung cancer
Horie, M., Saito, A., Ohshima, M., Suzuki, H. I., & Nagase, T. (2016) · Cancer Science · doi:10.1111/cas.13078 · Cited by 117
Predictive approaches for drug combination discovery in cancer
Tonekaboni, S. A. M., Ghoraie, L. S., Manem, V. S., & Haibe‐Kains, B. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbw104 · Cited by 118
Rzymski, T., Mikuła, M., Żyłkiewicz, E., Dreas, A., Wiklik, K., Gołas, A., Wójcik, K., Masiejczyk, M., Wróbel, A., Dolata, I., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16810 · Cited by 117
Recent advances in combinatorial drug screening and synergy scoring
Pemovska, T., Bigenzahn, J. W., & Superti‐Furga, G. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.07.008 · Cited by 122
Joung, J., Kirchgatterer, P. C., Singh, A., Cho, J. H., Nety, S. P., Larson, R. C., Macrae, R. K., Deasy, R., Tseng, Y., Maus, M. V., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29205-8 · Cited by 119
Giacomini, C. P., Sun, S., Varma, S., Shain, A. H., Giacomini, M. M., Balagtas, J. M. S., Sweeney, R. T., Lai, E., Fitz, C. D. V., Forster, A. D., et al. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003464 · Cited by 117
Cortés‐Ciriano, I., Ain, Q. U., Subramanian, V., Lenselink, E. B., Méndez‐Lucio, O., IJzerman, A. P., Wohlfahrt, G., Prūsis, P., Malliavin, T. E., van Westen, G. J. P., et al. (2014) · MedChemComm · doi:10.1039/c4md00216d · Cited by 119
Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers
García, P. D., Langowski, J. L., Wang, Y., Chen, M., Castillo, J., Fanton, C. P., Ison-Dugenny, M., Zavorotinskaya, T., Dai, Y., Lü, J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2062 · Cited by 117
Self-citationLi, H., Wawrose, J. S., Gooding, W. E., Garraway, L. A., Lui, V. W. Y., Peyser, N. D., & Grandis, J. R. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0396 · Cited by 116
Self-citationCui, H., Zhang, Y., Zhang, Q., Chen, W., Zhao, H., & Liang, J. (2017) · Cancer Medicine · doi:10.1002/cam4.1180 · Cited by 116
The KDM3A–KLF2–IRF4 axis maintains myeloma cell survival
Ohguchi, H., Hideshima, T., Bhasin, M., Görgün, G., Santo, L., Cea, M., Samur, M., Mimura, N., Suzuki, R., Tai, Y.-T., et al. (2016) · Nature Communications · doi:10.1038/ncomms10258 · Cited by 116
Pan-cancer EMT-signature identifies RBM47 down-regulation during colorectal cancer progression
Rokavec, M., Kaller, M., Horst, D. A., & Hermeking, H. (2017) · Scientific Reports · doi:10.1038/s41598-017-04234-2 · Cited by 115
Quanz, M., Bender, E., Kopitz, C., Grünewald, S., Schlicker, A., Schwede, W., Eheim, A. L., Toschi, L., Neuhaus, R., Richter, C., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1253 · Cited by 117
Hagemann, U. B., Ellingsen, C., Schuhmacher, J., Kristian, A., Mobergslien, A., Cruciani, V., Wickstroem, K., Schatz, C. A., Kneip, C., Golfier, S., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3476 · Cited by 117
Liu, Y., Nanni, L., Sungalee, S., Zufferey, M., Tavernari, D., Mina, M., Ceri, S., Oricchio, E., & Ciriello, G. (2021) · Nature Communications · doi:10.1038/s41467-021-22666-3 · Cited by 112
Salvage of ribose from uridine or RNA supports glycolysis in nutrient-limited conditions
Skinner, O. S., Blanco-Fernández, J., Goodman, R. P., Kawakami, A., Shen, H., Kemény, L. V., Joesch-Cohen, L. M., Rees, M. G., Roth, J. A., Fisher, D. E., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00774-2 · Cited by 120
CDA directs metabolism of epigenetic nucleosides revealing a therapeutic window in cancer
Zauri, M., Berridge, G., Thézénas, M., Pugh, K., Goldin, R. D., Kessler, B. M., & Kriaučionis, S. (2015) · Nature · doi:10.1038/nature14948 · Cited by 112
Integrative and Personalized QSAR Analysis in Cancer by Kernelized Bayesian Matrix Factorization
Ammad-ud-din, M., Georgii, E., Gönen, M., Laitinen, T., Kallioniemi, O., Wennerberg, K., Poso, A., & Samuel Kaski, A. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500152b · Cited by 114
Vogel, C. F. A., & Haarmann‐Stemmann, T. (2017) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2017.02.004 · Cited by 123
An expanded landscape of human long noncoding RNA
Jiang, S., Cheng, S., Ren, L., Wang, Q., Kang, Y.-J., Ding, Y., Hou, M. L., Yang, X., Lin, Y., Liang, N., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz621 · Cited by 116
Wooten, D. J., Groves, S. M., Tyson, D. R., Liu, Q., Lim, J. S., Albert, R., Lopez, C. F., Sage, J., & Quaranta, V. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1007343 · Cited by 118
Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression
Chakraborty, G., Armenia, J., Mazzu, Y. Z., Nandakumar, S., Stopsack, K. H., Atiq, M. O., Komura, K., Jehane, L. E., Hirani, R., Chadalavada, K., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1570 · Cited by 116
Kao, T., Wu, C.-C., Phan, N. N., Liu, Y.-H., Ta, H. D. K., Anuraga, G., Wu, Y.-F., Lee, K., Chuang, J., & Wang, C. (2021) · Aging · doi:10.18632/aging.203345 · Cited by 114
Merlotti, A., Sadacca, B., Arribas, Y. A., Ngoma, M., Burbage, M., Goudot, C., Houy, A., Rocañín-Arjó, A., Lalanne, A. I., Seguin‐Givelet, A., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.abm6359 · Cited by 118
Large Scale Foundation Model on Single-cell Transcriptomics
Hao, M., Gong, J., Zeng, X., Liu, C., Guo, Y., Cheng, X., Wang, T., Ma, J., Song, L., & Zhang, X. (2023) · doi:10.1101/2023.05.29.542705 · Cited by 639
Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics
Collins, D. C., Sundar, R., Lim, J. S. J., & Yap, T. A. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.10.012 · Cited by 116
PARP Trapping Beyond Homologous Recombination and Platinum Sensitivity in Cancers
Murai, J., & Pommier, Y. G. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055914 · Cited by 114
Metabolic gene alterations impact the clinical aggressiveness and drug responses of 32 human cancers
Sinkala, M., Mulder, N., & Martin, D. P. (2019) · Communications Biology · doi:10.1038/s42003-019-0666-1 · Cited by 111
Human Motion Driven Self-Powered Photodynamic System for Long-Term Autonomous Cancer Therapy
Liu, Z., Xu, L., Zheng, Q., Kang, Y., Shi, B., Jiang, D., Li, H., Qu, X., Fan, Y., Wang, Z. L., et al. (2020) · ACS Nano · doi:10.1021/acsnano.0c00675 · Cited by 113
MHC class II transactivator CIITA induces cell resistance to Ebola virus and SARS-like coronaviruses
Bruchez, A. M., Sha, K., Johnson, J. C., Chen, L., Stefani, C., McConnell, H., Gaucherand, L., Prins, R., Matreyek, K. A., Hume, A. J., et al. (2020) · Science · doi:10.1126/science.abb3753 · Cited by 109
Methionine synthase is essential for cancer cell proliferation in physiological folate environments
Sullivan, M. R., Darnell, A. M., Reilly, M. F., Kunchok, T., Joesch-Cohen, L. M., Rosenberg, D. W., Ali, A., Rees, M. G., Roth, J. A., Lewis, C. A., et al. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00486-5 · Cited by 120
Advancing pharmaceutical research: A comprehensive review of cutting-edge tools and technologies
Chen, J., Lin, A., & Luo, P. (2024) · Current Pharmaceutical Analysis · doi:10.1016/j.cpan.2024.11.001 · Cited by 112
Unni, A. M., Harbourne, B., Oh, M. H., Wild, S. A., Ferrarone, J. R., Lockwood, W. W., & VARMUS, H. E. (2018) · eLife · doi:10.7554/elife.33718 · Cited by 111
L’Abbate, A., Macchia, G., D’Addabbo, P., Lonoce, A., Tolomeo, D., Trombetta, D., Kok, K., Bartenhagen, C., Whelan, C. W., Palumbo, O., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku590 · Cited by 109
MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels
Lu, Y., Hu, Z., Mangala, L. S., Stine, Z. E., Hu, Z., Jiang, D., Xiang, Y., Zhang, Y., Pradeep, S., Rodriguez‐Aguayo, C., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0815 · Cited by 111
Vučetić, M., Cormerais, Y., Parks, S. K., & Pouysségur, J. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00319 · Cited by 121
Metadata
- Authors
- Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., Reddy, A., Liu, M., Murray, L., Berger, M. F., Monahan, J. E., Morais, P., Meltzer, J., Korejwa, A., Jané-Valbuena, J., Mapa, F. A., Thibault, J., Bric-Furlong, E., Raman, P., Shipway, A., Engels, I. H., Cheng, J., Yu, G. K., Yu, J., Aspesi, P., de Silva, M., Jagtap, K., Jones, M. D., Wang, L., Hatton, C., Palescandolo, E., Gupta, S., Mahan, S., Sougnez, C., Onofrio, R. C., Liefeld, T., MacConaill, L., Winckler, W., Reich, M., Li, N., Mesirov, J. P., Gabriel, S. B., Getz, G., Ardlie, K., Chan, V., Myer, V. E., Weber, B. L., Porter, J., Warmuth, M., Finan, P., Harris, J. L., Meyerson, M., Golub, T. R., Morrissey, M. P., Sellers, W. R., Schlegel, R., & Garraway, L. A.
- Affiliations
- Broad Institute (US)
- Genomics Institute of the Novartis Research Foundation (US)
- Harvard University (US)
- Corresponding author
- Schlegel, Robert
- Garraway, Levi A.
- ORCID
- Barretina, Jordi
- Stransky, Nicolas
- Venkatesan, Kavitha
- Wilson, Christopher J.
- Lehár, Joseph
- Kryukov, Gregory V.
- Sonkin, Dmitriy
- Reddy, Anupama
- Liu, Manway
- Murray, Lauren
- Berger, Michael F.
- Monahan, John E.
- Mapa, Felipa A.
- Raman, Pichai
- Yu, Guoying K.
- Yu, Jianjun
- Aspesi, Peter
- Jones, Michael D.
- Wang, Li
- Gupta, Supriya
- Liefeld, Ted
- MacConaill, Laura
- Winckler, Wendy
- Reich, Michael
- Li, Nanxin
- Mesirov, Jill P.
- Gabriel, Stacey B.
- Getz, Gad
- Ardlie, Kristin
- Chan, Vivien
- Myer, Vic E.
- Weber, Barbara L.
- Meyerson, Matthew
- Golub, Todd R.
- Sellers, William R.
- Garraway, Levi A.
- Venue
- Nature
- Published
- 2012-03-28
- Volume
- 483
- Issue
- 7391
- Pages
- 603-607
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3320027
- OpenAlex
- W2043398720
- Cited by
- 7,950
- References
- 28
- Citations by year
- 2026: 361 · 2025: 501 · 2024: 617 · 2023: 719 · 2022: 723 · 2021: 839 · 2020: 682 · 2019: 687 · 2018: 628 · 2017: 500 · 2016: 516 · 2015: 436 · 2014: 348 · 2013: 283 · 2012: 103
- FWCI
- 124.24
- Type
- journal article
- Language
- en
- Update notices
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health (DP2OD002750)
- National Human Genome Research Institute (U54HG003067)
- National Cancer Institute (R33CA155554, R33CA126674)
- National Institute of General Medical Sciences (R01GM074024)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- Cancer Cell Line Encyclopedia, anticancer drug sensitivity, drug resistance, cancer cell lines, Ewing sarcoma, PARP inhibitors, SLFN11, topoisomerase inhibitors, MEK inhibitors, NRAS mutation, aryl hydrocarbon receptor, gene expression profiles, chromosomal copy number, predictive modeling, precision oncology
- MeSH terms
- Antineoplastic Agents, Chromosomes, Human, Clinical Trials as Topic, Drug Screening Assays, Antitumor, Encyclopedias as Topic, Humans, Models, Biological, Neoplasms, Pharmacogenetics, Plasma Cells, Genes, ras, Genome, Human, Gene Expression Regulation, Neoplastic, Databases, Factual, Sequence Analysis, DNA, Receptor, IGF Type 1, Receptors, Aryl Hydrocarbon, Cell Lineage, Gene Expression Profiling, Mitogen-Activated Protein Kinase Kinases, Genomics, Cell Line, Tumor, Precision Medicine, Topoisomerase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
